Skip to main content
Erschienen in: Supportive Care in Cancer 10/2016

03.05.2016 | Original Article

Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison

verfasst von: Ashley M. Nelson, Brian D. Gonzalez, Heather S. L. Jim, Julie M. Cessna, Steven K. Sutton, Brent J. Small, Mayer N. Fishman, Babu Zachariah, Paul B. Jacobsen

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although fatigue is a common problem for men with prostate cancer undergoing androgen deprivation therapy (ADT), there has been little systematic research on this issue. The present study examined changes in fatigue among prostate cancer patients receiving ADT compared to controls and predictors of heightened fatigue in ADT patients.

Methods

Prostate cancer patients treated with ADT (ADT+ group, n = 60) completed assessments of fatigue prior to or just after ADT initiation (baseline) and 6 and 12 months later. Prostate cancer patients treated with prostatectomy only (ADT− group, n = 85) and men without cancer (CA− group, n = 86) matched on age and education completed assessments at similar intervals.

Results

Group-by-time interactions for fatigue severity, interference, and duration were observed when comparing the ADT+ group to the controls. Groups did not differ at baseline; however, the ADT+ group reported worse fatigue at 6 and 12 months. The same pattern was observed for changes in the prevalence of clinically meaningful fatigue and the extent of clinically meaningful change in fatigue. Within the ADT+ group, higher baseline comorbidity scores were associated with greater increases in fatigue interference, and higher baseline Gleason scores were associated with greater increases in fatigue duration.

Conclusions

Prostate cancer patients receiving ADT demonstrate a trajectory of worsened fatigue during the first 12 months following treatment initiation relative to the controls. Greater comorbidities and higher Gleason scores at baseline appear to be risk factors for heightened fatigue during the first year following ADT initiation. Results highlight important time points for implementation of interventions aimed at fatigue reduction.
Literatur
1.
Zurück zum Zitat Irani J, Salomon L, Oba R, Bouchard P, Mottet N (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomized trial. Lancet Oncol 11:147–154. doi:10.1016/S1470-2045(09)70338-9 CrossRefPubMed Irani J, Salomon L, Oba R, Bouchard P, Mottet N (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomized trial. Lancet Oncol 11:147–154. doi:10.​1016/​S1470-2045(09)70338-9 CrossRefPubMed
2.
Zurück zum Zitat Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603CrossRefPubMed Smith MR, Finkelstein JS, McGovern FJ et al (2002) Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599–603CrossRefPubMed
5.
Zurück zum Zitat Pirl WF, Greer JA, Goode M, Smith MR (2008) Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho-Oncol 17:148–153. doi:10.1002/pon.1206 CrossRef Pirl WF, Greer JA, Goode M, Smith MR (2008) Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psycho-Oncol 17:148–153. doi:10.​1002/​pon.​1206 CrossRef
6.
Zurück zum Zitat Cherrier MM, Aubin S, Higano CS (2009) Cognitive and mood changes in men undergoing intermittent combined androgen blockade for nonmetastatic prostate cancer. Psycho-Oncol 18:237–247. doi:10.1002/pon.1401 CrossRef Cherrier MM, Aubin S, Higano CS (2009) Cognitive and mood changes in men undergoing intermittent combined androgen blockade for nonmetastatic prostate cancer. Psycho-Oncol 18:237–247. doi:10.​1002/​pon.​1401 CrossRef
8.
Zurück zum Zitat Storey DJ, McLaren DB, Atkinson MA et al (2012) Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol 23:1542–1549. doi:10.1093/annonc/mdr447 CrossRefPubMed Storey DJ, McLaren DB, Atkinson MA et al (2012) Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol 23:1542–1549. doi:10.​1093/​annonc/​mdr447 CrossRefPubMed
12.
Zurück zum Zitat Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73–84CrossRefPubMed Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW (1996) Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73–84CrossRefPubMed
13.
Zurück zum Zitat Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7:301–310CrossRefPubMed Hann DM, Jacobsen PB, Azzarello LM et al (1998) Measurement of fatigue in cancer patients: development and validation of the Fatigue Symptom Inventory. Qual Life Res 7:301–310CrossRefPubMed
14.
Zurück zum Zitat National Comprehensive Cancer Network: NCCN Clinical practice guidelines in oncology: cancer-related fatigue (version 2.2015). www.nccn.org National Comprehensive Cancer Network: NCCN Clinical practice guidelines in oncology: cancer-related fatigue (version 2.2015). www.​nccn.​org
17.
Zurück zum Zitat Lee M, Jim HS, Fishman M et al (2015) Depressive symptomology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psycho-Oncol 24:472–477. doi:10.1002/pon.3608 CrossRef Lee M, Jim HS, Fishman M et al (2015) Depressive symptomology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Psycho-Oncol 24:472–477. doi:10.​1002/​pon.​3608 CrossRef
18.
Zurück zum Zitat Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347. doi:10.1200/JCO.2009.23.2488 CrossRefPubMed Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347. doi:10.​1200/​JCO.​2009.​23.​2488 CrossRefPubMed
22.
Zurück zum Zitat Santa Mina D, Alibhai SMH, Matthew AG et al (2013) A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act 21:455–478CrossRefPubMed Santa Mina D, Alibhai SMH, Matthew AG et al (2013) A randomized trial of aerobic versus resistance exercise in prostate cancer survivors. J Aging Phys Act 21:455–478CrossRefPubMed
24.
Zurück zum Zitat Montgomery GH, Kangas M, David D et al (2009) Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. Health Psychol 28:317–322. doi:10.1037/a0013582 CrossRefPubMed Montgomery GH, Kangas M, David D et al (2009) Fatigue during breast cancer radiotherapy: an initial randomized study of cognitive-behavioral therapy plus hypnosis. Health Psychol 28:317–322. doi:10.​1037/​a0013582 CrossRefPubMed
27.
Zurück zum Zitat Paulsen O, Klepstad P, Rosland JH et al (2014) Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 29:3221–3229. doi:10.1200/JCO.2013.54.3926 CrossRef Paulsen O, Klepstad P, Rosland JH et al (2014) Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial. J Clin Oncol 29:3221–3229. doi:10.​1200/​JCO.​2013.​54.​3926 CrossRef
Metadaten
Titel
Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison
verfasst von
Ashley M. Nelson
Brian D. Gonzalez
Heather S. L. Jim
Julie M. Cessna
Steven K. Sutton
Brent J. Small
Mayer N. Fishman
Babu Zachariah
Paul B. Jacobsen
Publikationsdatum
03.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3241-z

Weitere Artikel der Ausgabe 10/2016

Supportive Care in Cancer 10/2016 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.